Projects
Impact of extracellular matrix organization in the tumor environment on efficacy of immunotherapy in DNA mismatch repair deficient tumors Ghent University
Immunotherapy is revolutionizing the clinical management of multiple cancer types including DNA mismatch repairdeficient
tumors (Galluzi et al., 2018). However, even in this preselected group of patients, good and complete response
are achieved in only onefifth of the patients (Le et al., 2016; Le et al., 2017). Thus, there are still enormous opportunities
for ...
Impact of extracellular matrix organization in the tumor environment on efficacy of immunotherapy in DNA mismatch repair deficient tumors. University of Antwerp
Developing a novel synergistic approach of chemotherapy and immunotherapy to enhance the anti-tumor immune response in non-small cell lung cancer. University of Antwerp
Dual epigenetic targeting and immunotherapy to fight against cancer Vrije Universiteit Brussel
Recent evidence further suggests that these drugs have immunomodulatory properties and synergize with immunotherapy, representing another major breakthrough in cancer therapy. We ...
Improving immunotherapy via tumor vessel normalization by blocking endothelial cell glycolysis KU Leuven
Traditional anti-angiogenesis strategies destroy tumor vessels. Their success is restricted by toxicity and resistance. The need for new anti-angiogenic strategies with fundamental distinct mechanisms is timely. An alternative therapeutic paradigm is tumor vessel normalization (TVN). By healing disorganized vessels, TVN improves perfusion and oxygenation, tightens the leaky vascular wall, thus reducing metastasis and enhancing chemotherapy ...
Role of combined chemo- and immunotherapy in early breast cancer KU Leuven
Cancer treatment is often based on combined locoregional and systemic therapy in order to achieve a maximum disease-free and overall survival rate with lowest toxic side-effects. Although a multidisciplinary treatment package is offered, up to 25% of early breast cancer patient will develop metastases in spite of optimal treatment. Tumour resistance to systemic therapy and dysregulation of the host-anti-tumour immune response have been linked ...